
BMO Reiterates Positive Outlook on Eli Lilly and Schlumberger Stocks
BMO Financial Group has maintained its outperform ratings for Eli Lilly and Schlumberger, citing strong strategic moves in their recent corporate acquisitions. The analyst firm highlighted the Merida and Kelvion deals as catalysts for future growth and market positioning.


